Texas Standards for TB Prevention and Control
- Texas TB Control Plan: Standards of Performance for the Prevention and Control of Tuberculosis (
284 KB)
- Signed Memorandum for Standing Delegation Orders and Procedures ( 17 KB)
- Standing Delegation Orders and Procedures for Nurses ( 461 KB)
- Standing Delegation Orders and Procedures for Directly Observed Therapy (
33 KB)
- Standing Delegation Orders and Procedures for TB Skin Testing ( 127 KB)
Texas TB Policy and Procedures
- Cohort Review Policy ( 45 KB)
CDC Recommendations and Guidelines, by category
Current CDC publications for the prevention and control of TB organized by the following categories:
layout
Control and Elimination
|
These guidelines and recommendations address the obstacles and opportunities for controlling and eliminating TB in the United States, including the essential components of TB prevention and control programs, and the need to address TB in low-incidence areas of the United States and in communities with at-risk minority populations.
|
Diagnosis
|
These diagnostic standards provide a practical guide and statement of principles for all persons involved in the care of patients with TB. They cover transmission of mycobacterium tuberculosis, clinical manifestations of TB, diagnostic microbiology, tuberculin skin test, definitions of TB disease and latent infection, and treatment of TB and TB infection.
|
HIV/AIDS
|
These guidelines update previous CDC recommendations for the diagnosis, treatment, and prevention of TB among adults and children coinfected with HIV in the United States.
|
Infection Control
|
Transmission of mycobacterium tuberculosis is a risk for patients and health care workers in healthcare facilities. These guidelines recommend strategies for reducing this risk in healthcare facilities.
|
Multidrug-Resistant TB (MDR)
|
Outbreaks of multidrug-resistant TB (MDR) pose a public health problem and require rapid attention. These guidelines present an action plan to specifically address this problem and cover the management of persons exposed to MDR.
|
Testing
|
Targeted tuberculin testing for latent tuberculosis infection (LTBI) is a strategic component of TB control that identifies persons at high risk for TB who would benefit by treatment of LTBI, if detected. These guidelines provide new recommendations for targeted tuberculin testing and treatment regimens for LTBI. Guidelines are also given to screening for TB and TB infection in high-risk populations.
|
Treatment
|
These guidelines address treatment regimens for TB among adults, children, persons coinfected with HIV, persons exposed to MDR, and LTBI.
|
Vaccines
|
These guidelines discuss the role of vaccines in TB prevention and control in the United States. Bacillus of Calmette and Guerin (BCG) is not recommended for programmatic use in the United States. Recognizing the importance of TB vaccines, the ACET recommends that public agencies and vaccine manufacturers develop a comprehensive strategy for new TB vaccine development.
|
All categories
|
View a list of all categories for which the CDC has issued guidelines and recommendations for the prevention, treatment, and control of TB.
|
Back to Top
CDC TB Publications
Recommendations for Use of an Isoniazid–Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection
From CDC's MMWR Weekly; December 9, 2011 / 60(48);1650-1653
Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010
From CDC's MMWR Recommendations and Reports; June 25, 2010 / 59(RR05);1-25
Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis
From CDC's MMWR Weekly; January 16, 2009 / 58(01);7-10
Plan to Combat Extensively Drug-Resistant Tuberculosis
From CDC's MMWR Recommendations and Reports; February 13, 2009; 58 (RR-03); 1-43
CDC Immigration Requirements: Technical Instructions for Tuberculosis Screening and Treatment (PDF)
From CDC
Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC
From CDC’s MMWR Recommendations and Reports 2006; July 7, 2006 / Vol. 55 (RR09); 1-44
Guidelines for Using the QuantiFERON-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States
From CDC's MMWR Recommendations and Reports; December 16, 2005; 54(No. RR-15): 49—55.
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis
From Centers for Disease Control and Prevention's (CDC) MMWR Recommendations and Reports: December 16, 2005 / Vol. 54(RR15): 1-37
Controlling Tuberculosis in the United States – Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America
From CDC’s MMWR: November 4, 2005 / Vol. 54(RR12): 1-81
Guidelines for Preventing the Transmission of Mycobacterium tuberculosisin Health-Care Settings, 2005
From CDC’s MMWR Recommendations and Reports, December 30, 2005 / Vol. 54 (RR17); 1-141
Slide Set — Guidelines for Preventing the Transmission of M. tuberculosis in Health-Care Settings, 2005
From DTBE
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC
From CDC’s MMWR Recommendations and Reports 2005; December 16, 2005 / Vol. 54 (RR15)/ 1-37
Treatment of Tuberculosis
American Thoracic Society, CDC, and Infectious Diseases Society of America
MMWR: June 20, 2003 / Vol. 52 (RR11): 1-77
Appendix B-Tuberculosis (TB) risk assessment worksheet (PDF)
From DTBE
TB Guidelines
From DTBE, a listing of all TB Guidelines issued from the division
Progressing Toward Tuberculosis Elimination in Low-Incidence Areas of the United States - Recommendations of the Advisory Council for the Elimination of Tuberculosis
From CDC’s MMWR Recommendations and Reports: May 3, 2002 / Vol. 51 (RR05);1-16
Diagnostic Standards/Classification of TB in Adults and Children (PDF)
American Journal of Respiratory Care and Critical Care Medicine, 2000; Vol. 161:1376-1395.
Back to Top